Skip to main content

Table 4 HPA haplotypes of HPA 1–3 in patients and controls

From: Association of human platelet alloantigens encoding gene polymorphisms with the risk of Coronary artery disease in Iranian patients

Haplotypesa

Frequencies

Association test

HPA1

HPA2

HPA3

Hap.freq

CAD (freq)

Hap.freq Controls (freq)

χ2

P valueb

Pcc

OR (95% CI)*

a

a

a

193 (0.482)

87 (0.437)

0.947

0.330597

0.910024

1.186 (0.84–1.67)

a

a

b

125 (0.313)

73 (0.363)

1.672

0.196024

0.729941

0.789 (0.55–1.13)

a

b

a

23 (0.058)

12 (0.059)

0.007

0.931565

1

0.969 (0.47–1.99)

a

b

b

22 (0.054)

6 (0.031)

1.639

0.200514

0.738865

1.804 (0.72–4.50)

b

a

a

17 (0.042)

15 (0.073)

2.743

0.097746

0.460523

0.547 (0.26–1.12)

b

a

b

15 (0.037)

3 (0.016)

2.023

0.155039

0.636068

2.357 (0.69–7.95)

b

b

a

2 (0.006)

4 (0.020)

–

–

 

–

b

b

b

3 (0.008)

0 (0.000)

–

–

 

–

  1. CAD coronary artery disease
  2. *95% confidence interval for difference between Hap.freq case–control; If a CI does not contain 0, frequencies of haplotypes in case and control groups are significantly different at α = 0.05
  3. aHPA haplotype (HPA1/HPA2/HPA3) frequency determined by the maximum likelihood method
  4. bFisher’s exact test
  5. cPc = corrected P, according to the Bonferroni method [Pc = 1 − (1 – P)n], where n = number of comparisons
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us